Isoniazid-phytochemical conjugation: A new approach for potent and less toxic anti-TB drug development.

Mycobacterium tuberculosis (Mtb) causes one of the most grievous pandemics infectious disease, tuberculosis (TB), with long-term morbidity and high mortality. The emergence of drug-resistant Mtb strains, and the co-infection with human immunodeficiency virus, challenges the current WHO-TB stewardship programs. The first-line anti-TB drugs, isoniazid (INH) and rifampicin (RIF) have become extensively obsolete in TB control from chromosomal mutations during the last decades. However, based on clinical-trial statistics, the production of well-tolerated anti-TB drug(s) is miserably low. Alternately, semi-synthesis or structural modifications of first-line obsolete antitubercular drugs remain as the versatile approach for getting some potential medicines. The use of any suitable phytochemical with INH in a hybrid formulation could be an ideal approach for the development of potent anti-TB drug(s). The primary objective of this review is to highlight and analyze available on INH-phytochemical hybrid research works as an alternative method. The utilization of phytochemicals through chemical conjugation is a new trend towards the development of safer/ non-toxic anti-TB drugs.